Comparative in-vitro activity of CP-99219, a new quinolone, against respiratory pathogens

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 4, 1996, Pages 803-808

  Sefton, A M ^a   Maskell, J P ^a   Seymour, A C ^a   Minassian, M ^a   Williams, J D ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFALOTIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; ERYTHROMYCIN; PENICILLIN G; QUINOLONE; SULTAMICILLIN; TETRACYCLINE; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BETA HEMOLYTIC STREPTOCOCCUS; CONTROLLED STUDY; DRUG ACTIVITY; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; NONHUMAN; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CEPHALOSPORINS; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; NAPHTHYRIDINES; PENICILLINS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0029880404     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.4.803     Document Type: Article

References (8)

1. Epiopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In-vitro activity of CP-99219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy, 37, 366-70.
2. Felmingham, D., Robbins, M. J., Ingley, K., Mathias, I., Bhogal, H., Leakey, A et al. (1994). In-vitro activity of CP-99219, a new fluoroquinolone against recent clinical bacterial isolates from patients with respiratory tract infections. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida. Abstract F12, p. 54, American Society for Microbiology, Washington DC.
3. Gooding, B. B. & Jones, R. N. (1993). In-vitro antimicrobial activity of CP-99219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy, 37, 349-53.
4. Klugman, K. P. & Wasas, A. (1994). In-vitro activity of the fluoroquinolone CP-99219 against penicillin-resistant Streptococcus pneumoniae. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida. Abstract F16, p. 54, American Society for Microbiology, Washington DC.
5. Neu H. C. & Chin, N-X. (1994). In-vitro activity of the new fluoroquinolone CP-99219. Antimicrobial Agents and Chemotherapy, 38, 2615-22.
6. Olsson-Liljequist, B., Hoffman, B. M. & Hedlund, J. (1994). Activity of CP-99219 against recent blood isolates of Streptococcus pneumoniae in Sweden. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida. Abstract F14, p. 54, American Society for Microbiology, Washington DC.
7. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1994). Activity of CP-99219 compared to eight quinolones against 112 penicillin-susceptible and resistant pneumococci. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, Florida. Abstract F2, p. 53, American Society for Microbiology, Washington DC.
8. Wise, R., Andrews, J. M. & Brenwald, N. (1994). The in-vitro activity, including that against Chlamydia, of CP-99219. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida. Abstract F22, p. 54. American Society for Microbiology, Washington DC.